Several studies have pursued the simultaneous dual targeting of EGFR and MET to overcome resistance in NSCLC treatment (Lee et al., 2023[10]; Yang et al., 2021[18]; Zhao et al., 2024[21]). Here, MET is linked to non-small cell lung carcinoma.